Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3319579
Max Phase: Preclinical
Molecular Formula: C36H45N3O6
Molecular Weight: 615.77
Molecule Type: Small molecule
Associated Items:
ID: ALA3319579
Max Phase: Preclinical
Molecular Formula: C36H45N3O6
Molecular Weight: 615.77
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: COc1ccc(C[C@H](NC(=O)[C@@H](C)NC(=O)C2=C(C)c3ccccc3C2)C(=O)N[C@@H](CC2CCCCC2)C(=O)[C@@]2(C)CO2)cc1
Standard InChI: InChI=1S/C36H45N3O6/c1-22-28-13-9-8-12-26(28)20-29(22)34(42)37-23(2)33(41)39-31(19-25-14-16-27(44-4)17-15-25)35(43)38-30(32(40)36(3)21-45-36)18-24-10-6-5-7-11-24/h8-9,12-17,23-24,30-31H,5-7,10-11,18-21H2,1-4H3,(H,37,42)(H,38,43)(H,39,41)/t23-,30+,31+,36-/m1/s1
Standard InChI Key: SIXKXOYWBKFIOX-CIEAOGCXSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 615.77 | Molecular Weight (Monoisotopic): 615.3308 | AlogP: 4.07 | #Rotatable Bonds: 13 |
Polar Surface Area: 126.13 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 3 |
#RO5 Violations: 1 | HBA (Lipinski): 9 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 12.08 | CX Basic pKa: | CX LogP: 5.08 | CX LogD: 5.08 |
Aromatic Rings: 2 | Heavy Atoms: 45 | QED Weighted: 0.29 | Np Likeness Score: 0.25 |
1. de Bruin G, Huber EM, Xin BT, van Rooden EJ, Al-Ayed K, Kim KB, Kisselev AF, Driessen C, van der Stelt M, van der Marel GA, Groll M, Overkleeft HS.. (2014) Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes., 57 (14): [PMID:25006746] [10.1021/jm500716s] |
Source(1):